Verrica Pharmaceuticals (NASDAQ:VRCA) Stock Price Up 0% - What's Next?

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Get Free Report) shot up 0% during trading on Monday . The stock traded as high as $0.63 and last traded at $0.61. 94,422 shares traded hands during mid-day trading, a decline of 84% from the average session volume of 585,165 shares. The stock had previously closed at $0.61.

Analysts Set New Price Targets

VRCA has been the topic of a number of research reports. Needham & Company LLC restated a "hold" rating on shares of Verrica Pharmaceuticals in a report on Wednesday, May 14th. Wall Street Zen raised shares of Verrica Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Finally, HC Wainwright restated a "neutral" rating on shares of Verrica Pharmaceuticals in a report on Tuesday, April 8th. Five equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $8.00.

Verrica Pharmaceuticals Trading Down 1.8%

The firm has a market cap of $55.59 million, a price-to-earnings ratio of -0.33 and a beta of 1.75. The stock has a fifty day moving average price of $0.52 and a 200 day moving average price of $0.65.

Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.04. The firm had revenue of $3.44 million for the quarter, compared to the consensus estimate of $2.53 million. Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%. On average, sell-side analysts forecast that Verrica Pharmaceuticals Inc. will post -1.46 EPS for the current year.

Institutional Investors Weigh In On Verrica Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. boosted its stake in Verrica Pharmaceuticals by 23.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 139,055 shares of the company's stock valued at $61,000 after purchasing an additional 26,308 shares during the period. AQR Capital Management LLC increased its holdings in shares of Verrica Pharmaceuticals by 306.7% during the 1st quarter. AQR Capital Management LLC now owns 58,711 shares of the company's stock worth $26,000 after purchasing an additional 44,275 shares during the period. Kovitz Investment Group Partners LLC acquired a new position in shares of Verrica Pharmaceuticals during the first quarter valued at about $45,000. Invesco Ltd. raised its position in shares of Verrica Pharmaceuticals by 64.8% during the first quarter. Invesco Ltd. now owns 74,388 shares of the company's stock valued at $33,000 after buying an additional 29,256 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Verrica Pharmaceuticals by 127.9% in the first quarter. Charles Schwab Investment Management Inc. now owns 99,505 shares of the company's stock valued at $44,000 after buying an additional 55,852 shares during the period. 42.45% of the stock is owned by institutional investors and hedge funds.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.